Cutaneous and ocular toxicology · 2026
Antiseizure drug-induced Stevens - Johnson syndrome and toxic epidermal necrolysis in children: a systematic review.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pal Biplab, Dutta Archita, Rohita, Kumar Sharma Krishana, Ravindra Babu Molakpogu, Chaudhary Vaibhav, Prakash Jay, Akanksha, Murti Krishna, Abubakar Md, Kumar Nitesh, Kumari Sweta, Sharma Neha
Аннотация
INTRODUCTION: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening severe reactions associated with antiseizure drugs (ASDs). This systematic review aimed to summarize the clinical characteristics, implicated drugs, management strategies, and outcomes of ASD-induced SJS/TEN in children.
METHODS: A systematic literature search was conducted in PubMed, Scopus, and Google Scholar from database inception to 2025 following PRISMA 2020 guidelines. Descriptive studies reporting pediatric patients (≤18 years) with ASD-induced SJS, TEN, or SJS-TEN overlap were included.
RESULTS: Thirty-four studies involving 37 pediatric patients were included. Among them, 22 patients (59.5%) developed SJS, 10 (27.0%) TEN, 4 (10.8%) SJS-TEN overlap, and 1 (2.7%) overlapping SJS/DRESS. Patients were aged 2.25-18 years, with males accounting for 20 (54.0%) of cases and females for 17 cases (45.9%). Lamotrigine was the most commonly implicated ASD (43.2%), followed by valproic acid (35.1%), and phenytoin and phenobarbitone (16.2% each). Monotherapy was reported in 64.8% of patients, while dual and triple therapy occurred in 27% and 8.1%, respectively. The lamotrigine-valproic acid combination was the most frequent high-risk regimen (21.6%). Most reactions occurred within 1-3 weeks of treatment initiation or dose escalation, especially during rapid titration. Drug withdrawal, supportive care, corticosteroids, and intravenous immunoglobulin were the main treatment strategies. Most patients recovered, although 1 death (2.7%) was reported.
CONCLUSION: ASD-induced SJS/TEN in children is rare but serious. Lamotrigine was the most frequently implicated ASD, with several cases occurring during early treatment or dose escalation, particularly in valproate-containing regimens. These findings reinforce the importance of cautious prescribing, appropriate titration, early recognition, and prompt withdrawal of the suspected drug.
METHODS: A systematic literature search was conducted in PubMed, Scopus, and Google Scholar from database inception to 2025 following PRISMA 2020 guidelines. Descriptive studies reporting pediatric patients (≤18 years) with ASD-induced SJS, TEN, or SJS-TEN overlap were included.
RESULTS: Thirty-four studies involving 37 pediatric patients were included. Among them, 22 patients (59.5%) developed SJS, 10 (27.0%) TEN, 4 (10.8%) SJS-TEN overlap, and 1 (2.7%) overlapping SJS/DRESS. Patients were aged 2.25-18 years, with males accounting for 20 (54.0%) of cases and females for 17 cases (45.9%). Lamotrigine was the most commonly implicated ASD (43.2%), followed by valproic acid (35.1%), and phenytoin and phenobarbitone (16.2% each). Monotherapy was reported in 64.8% of patients, while dual and triple therapy occurred in 27% and 8.1%, respectively. The lamotrigine-valproic acid combination was the most frequent high-risk regimen (21.6%). Most reactions occurred within 1-3 weeks of treatment initiation or dose escalation, especially during rapid titration. Drug withdrawal, supportive care, corticosteroids, and intravenous immunoglobulin were the main treatment strategies. Most patients recovered, although 1 death (2.7%) was reported.
CONCLUSION: ASD-induced SJS/TEN in children is rare but serious. Lamotrigine was the most frequently implicated ASD, with several cases occurring during early treatment or dose escalation, particularly in valproate-containing regimens. These findings reinforce the importance of cautious prescribing, appropriate titration, early recognition, and prompt withdrawal of the suspected drug.